Core Viewpoint - Senyi Medical Technology Co., Ltd. (referred to as "Senyi Intelligent") has officially submitted its listing application to the Hong Kong Stock Exchange under the 18C rule, aiming to capitalize on its position as a leading AI medical technology company in the global market [1] Group 1: Company Overview - Senyi Intelligent is recognized as the only company in the global AI medical industry that offers solutions ranging from L1 to L4 levels, showcasing its comprehensive technical research and development capabilities from data infrastructure to application layer algorithms and software [1] - The company has maintained a leading position in the Chinese medical industry for many years, primarily serving hospitals and medical groups, and is projected to be the largest hospital AI medical solution provider in China by 2024 revenue [1] - As of June 30, 2025, Senyi Intelligent has served over 750 hospitals, including more than 400 large hospitals [1] Group 2: Technology and Solutions - Senyi Intelligent has developed a full-stack technical framework covering L1 to L4 levels to address key challenges in the AI medical industry, providing multi-scenario AI medical solutions [2] - The company has successfully commercialized and deployed L1 to L3 level solutions, including data intelligence solutions (L1), AI-assisted solutions (L2), and AI agent solutions (L3) [2] - The company is focusing on the research and validation of L4 high-level autonomous intelligent solutions in collaboration with global ecosystem partners to accelerate commercialization and large-scale deployment [2] Group 3: Financial Performance - From 2022 to the first half of 2025, Senyi Intelligent reported revenues of approximately 144 million, 239 million, 292 million, and 91.08 million RMB, respectively, while incurring losses of approximately 376 million, 352 million, 207 million, and 103 million RMB during the same periods [3] - The R&D team consists of 137 employees, primarily located in Shanghai, Hangzhou, and Changchun, with a dynamic adjustment of recruitment and structure based on strategic and project needs [3] - R&D costs as a percentage of total revenue decreased from 94.6% in 2022 to 19.8% in the first half of 2025, indicating improved cost efficiency [3] Group 4: Use of Proceeds - The funds raised from the IPO are intended to enhance the company's R&D and innovation capabilities, improve existing products and solutions, boost commercialization efforts, establish a global channel network, acquire synergistic companies, and support working capital and other general corporate purposes [3]

智通财经APP获悉，据港交所9月30日披露，上海森亿医疗科技股份有限公司(简称：森亿智能)向港交所主板提交上市申请书， 中信建投国际、建银国际和交银国际为联席保荐人。 | | | | 截至12月31日止年度 | | | | | 截至6月30日止六個月 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 2022年 | | 2023年 | | 2024年 | | 2024年 | | 2025年 | | | | 人民幣元 | % | 人民幣元 | | 人民幣元 % | | 人民幣元 | 1 % | 人民幣元 | % | | | | | | | (人民幣千元,百分比除外) | | | | | | | | | | | | | | (未經審計) | | | | | 收入 | 143,748 | 100.0 | 239,110 | 100.0 | 291,850 | 100.0 | 91,085 | 100.0 | 112,345 | 100.0 | | 銷售成本 | (105,063) | (73.1) | (166 ...